Phaos Technology Cayman (POAS)
Market Price (5/30/2026): $0.5 | Market Cap: $-Sector: Health Care | Industry: Life Sciences Tools & Services
Phaos Technology Cayman (POAS)
Market Price (5/30/2026): $0.5Market Cap: $-Sector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -169% | Penny stockMkt Price is 0.5 High stock price volatilityVol 12M is 203% Key risksPOAS key risks include [1] significant going concern risk driven by a 91.1% revenue collapse, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -169% |
| Penny stockMkt Price is 0.5 |
| High stock price volatilityVol 12M is 203% |
| Key risksPOAS key risks include [1] significant going concern risk driven by a 91.1% revenue collapse, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 5/14/2026
Phaos Technology Cayman (POAS) stock has lost about 85% since 1/31/2026 because of the following key factors:
1. Significant Financial Deterioration and Going Concern Risk. Phaos Technology Cayman experienced a drastic 91.09% decline in revenue to 167,707 SGD in fiscal year 2025 (ending April 30, 2025), down from 1.88 million SGD in the previous year. Concurrently, losses escalated by 117.7% to -5.14 million SGD in 2025, resulting in a net income of -7.87 million USD for the last year. This severe financial downturn has raised substantial doubt about the company's ability to continue as a going concern.
2. Leadership Instability and Executive Departures. Just prior to the specified period, on January 16, 2026, both the Chief Executive Officer and Chief Operating Officer exited their positions, leading to an interim CEO, Gan Hong Loon, stepping in. Additionally, board resignations were announced, effective December 31, 2025. This significant turnover at the executive level contributed to investor uncertainty regarding the company's future leadership and strategic direction.
Show more
Phaos Technology Cayman (POAS) stock has lost about 85% since 1/31/2026 because of the following key factors:
1. Significant Financial Deterioration and Going Concern Risk. Phaos Technology Cayman experienced a drastic 91.09% decline in revenue to 167,707 SGD in fiscal year 2025 (ending April 30, 2025), down from 1.88 million SGD in the previous year. Concurrently, losses escalated by 117.7% to -5.14 million SGD in 2025, resulting in a net income of -7.87 million USD for the last year. This severe financial downturn has raised substantial doubt about the company's ability to continue as a going concern.
2. Leadership Instability and Executive Departures. Just prior to the specified period, on January 16, 2026, both the Chief Executive Officer and Chief Operating Officer exited their positions, leading to an interim CEO, Gan Hong Loon, stepping in. Additionally, board resignations were announced, effective December 31, 2025. This significant turnover at the executive level contributed to investor uncertainty regarding the company's future leadership and strategic direction.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| POAS | -86.5% | |
| Market (SPY) | 9.6% | -1.8% |
| Sector (XLV) | -3.0% | 7.7% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| POAS | ||
| Market (SPY) | 11.5% | 0.5% |
| Sector (XLV) | 4.5% | 5.4% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| POAS | ||
| Market (SPY) | 38.0% | 0.5% |
| Sector (XLV) | 8.3% | 5.4% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| POAS | ||
| Market (SPY) | 89.0% | 0.5% |
| Sector (XLV) | 17.7% | 5.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| POAS Return | - | - | - | - | -11% | -22% | -31% |
| Peers Return | 60% | -21% | 25% | -2% | 29% | 23% | 147% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| POAS Win Rate | - | - | - | - | 0% | 60% | |
| Peers Win Rate | 78% | 42% | 60% | 47% | 48% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| POAS Max Drawdown | - | - | - | - | - | -87% | |
| Peers Max Drawdown | -17% | -38% | -24% | -31% | -36% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, BRKR, KLAC, AMAT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
POAS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
POAS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Phaos Technology Cayman (POAS)
Phaos Technology Holdings (Cayman) Limited is an investment holding company incorporated on March 7, 2024, under the laws of the Cayman Islands. The Company through its subsidiary assembles and commercializes such advanced microscopy-related solutions, technologies and products. Using its patented microsphere-assisted technology, the Company can significantly increase the magnification of existing traditional optical microscopes compared to its competitors, hence allowing our clients to see beyond the optical limit in an effective manner. Currently, it is the only commercially available advanced optical microscope that can see below the 200nm optical limit, within a commercially viable working distance. Our business is primarily involved in the assembling and commercialization of advanced microscopy-related solutions, technologies and products tailored for precision measurement and magnification purposes. Our range of product includes optical microscopy solutions, featuring: i) Super-resolution imagers capable of achieving imaging down to 137nm; ii) Specialized microscopes designed to meet the diverse needs of various industries; and iii) Three-dimensional (“3-D”) real-time image magnifiers for enhanced visualization. Traditional optical microscopes are able to see up to 250nm, while our solution allows users to see up to 137nm. As a result, we believe that this is considered by the optical industry as a super resolution optical microscopy solution. In addition to our hardware offerings, we currently provide complimentary proprietary software, which is developed in-house. This software includes Artificial Intelligent (“AI”) components that allows our customers to perform recognition patterns for research, quality assurance and quality control (“QA/QC”), as well as diagnostics purposes. The in-house software is crafted to complement our product line to help ensure seamless integration and optimized performance for our customers. For the six months period ended October 31, 2023 and 2024, the provision of microscopy products contributed to 99.8% and 80.9% of our revenue, respectively. We distribute our microscopy products with software solutions through an extensive network of distributors, primarily in Vietnam and Singapore, and expanding across regions such as Southeast Asia and South Asia. Our microscopy solutions accommodate a diverse range of applications enabling us to serve a wide range of customer needs and capitalize on emerging growth opportunities in the region. Our diverse customer base primarily includes industries with usage in fields such as manufacturing, research & development, biomedical, semiconductors, Printed Circuit Board (“PCB”), electronics, precision engineering, injection molding, research, healthcare, QA/QC and diagnostics. Our business strategic focus involves strengthening our market position in Singapore and Vietnam, and progressively expanding into the Southeast Asian region. We believe in our strong corporate culture which emphasizes the creation of shareholder value. In the six months period ended October 31, 2024, business in Vietnam and Singapore contributed to 59.8% and 32.1% of our Group’s revenue, respectively. For the six months period ended October 31, 2023, our revenue was S$365,415. For the six months period ended October 31, 2024, our revenue was S$63,129. This is a reduction of 82.7% in revenue. Our net loss and accumulated deficit was S$1,535,175 and S$6,205,397, respectively, for October 31, 2023, while our net loss and accumulated deficit was S$2,019,092 (US$1,526,234) and S$9,049,158 (US$6,840,259) for October 31, 2024. This signifies an increase of 31.5% and 45.8% for net loss and accumulated deficit. The increase in net loss is driven by a decrease in revenue arising from a reduction in sales orders from our largest customers, resulting in additional resources are allocated to focus on regional expansion. and an increase in employee benefits expenses and other operating expenses from October 31, 2023 to October 31, 2024. We expect that the diversification of our customer base will allow us to increase and stabilize our product sales through a larger customer base and lower concentration of top customers which we are working actively to broaden. Service revenue increased as a result of maintenance-based contracts for our customers. As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward. Additional resources are allocated to focus on regional expansion in response to a reduction in sales orders from our largest customers. We expect that the diversification of our customer base will allow us to increase and stabilize our product sales through a larger customer base and lower concentration of top customers which we are working actively to broaden. Service revenue increased as a result of maintenance-based contracts for our customers. As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward. Our registered office in the Cayman Islands is at 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands. Our principal executive office is in Singapore.
AI Analysis | Feedback
Here are 1-3 brief analogies for Phaos Technology Cayman (POAS):
It's like **Zeiss for super-resolution optical microscopes.**
It's like **KLA Corporation for advanced optical inspection and precision measurement.**
AI Analysis | Feedback
- Super-resolution Imagers: Optical microscopy solutions capable of achieving imaging down to 137nm.
- Specialized Microscopes: Optical microscopes designed to meet the diverse needs of various industries.
- 3-D Real-time Image Magnifiers: Products for enhanced visualization through three-dimensional real-time image magnification.
- Proprietary AI Software: In-house developed software with Artificial Intelligent components for pattern recognition, quality assurance, quality control, and diagnostics.
- Maintenance Services: Post-sales maintenance-based contracts for their microscopy products and software solutions.
AI Analysis | Feedback
Major Customers of Phaos Technology Cayman (POAS)
Phaos Technology Cayman (POAS) sells its advanced microscopy solutions and proprietary software primarily to other companies through an extensive network of distributors. The provided background information does not name specific customer companies or their symbols. While the company mentions a reduction in sales orders from "our largest customers," these customers are not identified by name.
However, the company serves a diverse customer base across various industries. These can be broadly categorized as:
- Industrial and Manufacturing Sector: This category includes industries such as general manufacturing, semiconductors, Printed Circuit Board (PCB) manufacturing, electronics, precision engineering, injection molding, and applications for quality assurance and quality control (QA/QC).
- Research and Development (R&D): This encompasses clients involved in general research and development activities across various scientific and engineering fields.
- Biomedical and Healthcare Sector: This includes customers in fields such as biomedical research, healthcare services, and diagnostics.
AI Analysis | Feedback
nullAI Analysis | Feedback
Gan Hong Loon, Interim Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer, and Executive Director
Mr. Gan Hong Loon was appointed interim Chief Executive Officer of Phaos Technology Holdings (Cayman) Limited effective December 31, 2025. He also serves as the Chief Financial Officer, Principal Accounting Officer, and Executive Director. His appointment as a director is for a term of 5 years, effective upon the company's listing on the NYSE American.
Hook Seng Beh, Executive Chairman of the Board
Mr. Hook Seng Beh holds the position of Executive Chairman of the Board. He has an employment agreement with Phaos Technology Cayman, effective December 31, 2024. Through his ownership of TongHuai SG Enterprise Pte. Ltd and TongHuai SG2 Enterprise Pte. Ltd, he is expected to control over 50% of the total voting power of the company's shares after its initial public offering. He is also a guarantor for a company bank loan.
AI Analysis | Feedback
Key Business Risks for Phaos Technology Cayman (POAS)
- Significant Financial Deterioration and Going Concern Risk: Phaos Technology Cayman has experienced a drastic decline in revenue, with an 82.7% reduction for the six months ended October 31, 2024, compared to the same period in the previous year. This revenue collapse, alongside increasing net losses and accumulated deficits, raises substantial doubt about the company's ability to continue as a going concern. For fiscal year 2025, the company's revenue plummeted by 91.09%, and losses escalated by 117.7% to -$5.14 million compared to 2024.
- High Customer Concentration and Dependence on Key Accounts: The company's financial performance has been significantly impacted by a reduction in sales orders from its largest customers. Phaos Technology Cayman acknowledges this vulnerability and is actively working to diversify its customer base to stabilize product sales and reduce reliance on a concentrated group of top customers.
- Challenges of Operating with a Small Revenue Base in a Competitive Market: Phaos Technology Cayman operates with a small revenue base, which poses challenges for effective competition within a market characterized by intense competition from larger and more established companies. The company is allocating additional resources to regional expansion in response to declining sales, which, combined with increasing operating expenses, further strains its financial position amidst its small revenue base.
AI Analysis | Feedback
The company faces a clear emerging threat due to a significant and sudden reduction in sales orders from its largest customers. This has resulted in a drastic 82.7% decrease in revenue for the six months ended October 31, 2024, compared to the same period in 2023, and a corresponding increase in net loss and accumulated deficit. This suggests a potential loss of market share or demand among its key customer base, forcing the company to reallocate resources to regional expansion and customer diversification.
AI Analysis | Feedback
The addressable markets for Phaos Technology Cayman's main products and services are significant, particularly within the global and Asia Pacific microscopy sectors. The company specializes in advanced microscopy-related solutions, including super-resolution imagers, specialized microscopes, 3-D real-time image magnifiers, and proprietary software with Artificial Intelligence (AI) components. Their primary distribution is in Vietnam and Singapore, with expansion planned across Southeast Asia and South Asia. The global super-resolution microscopes market was valued at approximately USD 3.91 billion in 2024 and is projected to grow to nearly USD 7.57 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032. Another estimate places the global market at USD 4,371.8 million in 2025, reaching USD 11,973.3 million by 2035 with a CAGR of 10.6%. The Asia Pacific region is anticipated to experience the fastest growth in the super-resolution microscopes market, driven by expanding life sciences research, increasing numbers of research universities, and enhanced public funding. For the broader optical microscopes market, the global size was estimated at USD 3.82 billion in 2024 and is projected to reach USD 6.45 billion by 2033, with a CAGR of 6% from 2025 to 2033. The Asia Pacific optical microscopes market is expected to reach approximately USD 3,047.9 million by 2030, growing at a CAGR of 9.4% from 2024 to 2030. This growth in Asia Pacific is fueled by the presence of leading manufacturers in countries like Japan, a rising number of local producers in China and India, increasing demand from diagnostic centers, and expanding research and development (R&D) initiatives. More specifically, the ASEAN biological optical microscope market was valued at over USD 46.8 million in 2020 and is estimated to reach USD 74.7 million by the end of 2031, with Singapore expected to gain market share. The global microscope software market, which includes AI-integrated solutions like those offered by Phaos Technology Cayman, was valued at USD 897.8 million in 2024 and is expected to reach USD 2,294.8 million by 2033, demonstrating a CAGR of 10.44% during the forecast period from 2025 to 2033. In the Asia Pacific region, the microscope software market was valued at USD 180.30 million in 2024 and is anticipated to grow to USD 515.99 million by 2032, at a CAGR of 13.2%. Another projection indicates the Asia Pacific microscope software market is expected to reach USD 590.1 million by 2030.AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Phaos Technology Cayman (POAS)
- Expansion into New Markets: Phaos Technology Cayman intends to strengthen its market position in Singapore and Vietnam while progressively expanding into the broader Southeast Asian region. This regional expansion is expected to open new revenue streams.
- Diversification and Growth of Customer Base: The company plans to diversify its customer base to increase and stabilize product sales. This strategy aims to reduce reliance on a few large customers and broaden its market penetration, leading to increased sales orders.
- Growth in Service Revenue: Phaos Technology Cayman anticipates that service revenue, driven by maintenance-based contracts and an expanding product and software range, will contribute a greater percentage of its total revenue going forward.
- Expansion of Product and Software Range: The company's focus on growing its product and software range, including AI components for pattern recognition and enhanced visualization solutions, is expected to drive both new product sales and subsequent service revenue from these offerings.
AI Analysis | Feedback
nullTrade Ideas
Select ideas related to POAS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 316.37 |
| Mkt Cap | 183.2 |
| Rev LTM | 24,778 |
| Op Inc LTM | 5,459 |
| FCF LTM | 5,291 |
| FCF 3Y Avg | 5,247 |
| CFO LTM | 6,439 |
| CFO 3Y Avg | 6,548 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.0% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 6.2% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 4.7% |
| Op Inc Chg 3Y Avg | 3.7% |
| Op Mgn LTM | 19.2% |
| Op Mgn 3Y Avg | 20.2% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 26.0% |
| CFO/Rev 3Y Avg | 27.2% |
| FCF/Rev LTM | 18.4% |
| FCF/Rev 3Y Avg | 21.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 183.2 |
| P/S | 5.2 |
| P/Op Inc | 40.9 |
| P/EBIT | 33.5 |
| P/E | 35.1 |
| P/CFO | 44.7 |
| Total Yield | 2.8% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | 3.4% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.8% |
| 3M Rtn | 7.8% |
| 6M Rtn | 2.2% |
| 12M Rtn | 40.7% |
| 3Y Rtn | -5.7% |
| 1M Excs Rtn | -0.4% |
| 3M Excs Rtn | -2.4% |
| 6M Excs Rtn | -10.9% |
| 12M Excs Rtn | 12.8% |
| 3Y Excs Rtn | -90.1% |
Earnings Returns History
Updated 5/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 5/29/2026